Investor Presentation - First Six Months of 2021

12 Investor presentation First six months of 2021 Two phase 3 trials have been initiated with oral semaglutide 14 mg in Alzheimer's Disease Alzheimer's Disease evoke and evoke+ trials have been initiated with 1,840 patients in each trial with a total of 3,680 patients Novo NordiskⓇ 3 mg 7 mg 14 mg oral semaglutide QD 14 mg oral semaglutide QD R 3 mg 7 mg 14 mg placebo QD 14 mg placebo QD 1:1 + Week 0 4 104 Treatment period ↑ Confirmatory endpoints 156 161 Follow-up Large unmet need within Alzheimer's Disease with ~85 million people living with mild cognitive impairment and dementia Objective To confirm superiority of oral sema vs placebo on the change in cognition and function in people with early Alzheimer's disease Primary endpoint Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score from baseline to end of 104 weeks of treatment • Inclusion criteria Early Alzheimer's Disease (mild cognitive impairment or mild dementia) Mini-Mental State Examination (MMSE) ≥ 22/30 • Age between 55-85 years • evoke+ has at least 20% with small vessel pathology Source: Alzheimer's Association report: 2020 Alzheimer's disease facts and figures, 2020 (16:391-460), AD: Alzheimer's disease; QD: Once-daily; MCI: mild cognitive impairment; Note: CDR-SB ratings are utilising in six domains are summed to provide a clinical measure = Sum of Boxes. These are: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care. CDR-SB Scores range from 0 to 18 with higher scores representing greater impairment

View entire presentation